Abbott is a global healthcare leader with a diverse portfolio of innovative technologies spanning diagnostics, medical devices, nutritionals, and branded generic medicines. With over 114,000 employees in more than 160 countries Abbott is driving life-changing advancements in healthcare. Abbott offers advanced diagnostic solutions to enhance patient care and operational efficiency. The ID NOW™ Platform delivers rapid, molecular results at the point of care, Utilising isothermal nucleic acid amplification technology (NAAT), it qualitatively detects infectious diseases in minutes, enabling faster clinical decision-making. The i-STAT 1 Wireless allows for rapid, wireless transmission of blood test results to EMR and LIS, facilitating quick treatment decisions. The i-STAT CHEM8+ delivers fast chemistries and electrolytes at the patient's side, transforming care delivery. The Afinion™ 2 provides efficient multi-assay testing, enabling immediate patient interaction and diabetes management. The Cholestech LDX™ Analyzer, a leader in point-of-care lipid and glucose testing, ensures accurate, actionable results. Together, these innovative products improve diagnostic capabilities and streamline healthcare processes, empowering medical professionals to make informed decisions swiftly.
BD (Becton, Dickinson and Company), a global medical technology leader, advances healthcare by improving medical discovery, diagnostics, and care delivery. With a commitment to enhancing clinician safety, lab accuracy, and research capabilities, BD partners worldwide to address health challenges, improve outcomes, lower costs, and expand healthcare access. BD leverages its extensive research and production expertise to develop near-patient testing solutions for pathogens such as RSV, influenza A+B, and group A strep (GAS). The BD Veritor™ Plus system delivers lab-quality immunoassay results within minutes, enhancing diagnostic workflows in physician offices, clinics, hospitals, and IDNs. This system enables rapid review of patient results, facilitating timely treatment decisions. It detects infectious diseases, including influenza A+B, RSV, and GAS, at the point of care, aiding early intervention. Additionally, the BD Veritor™ System for Rapid Detection of SARS-CoV-2 qualitatively detects COVID-19 antigens in nasal swabs from symptomatic patients.
bioMérieux, a global leader in In vitro diagnostics for 60 years, operates in 45 countries and serves over 160 countries through a vast distributor network. The company offers diagnostic solutions—including systems, reagents, software, and services—to identify disease sources and contamination, enhancing patient health and consumer safety. Primarily used for diagnosing infectious diseases, their products also detect microorganisms in agri-food, pharmaceutical, and cosmetic products. BIOFIRE® FIREWORKS™ revolutionizes diagnostic management with its centralized data portal, offering deep insights into BIOFIRE® System performance, pathogen surveillance, and workflow efficiency. Meanwhile, the BIOFIRE® SPOTFIRE® Respiratory Panels enable rapid on-site PCR testing, providing comprehensive results for various pathogens within approximately 15 minutes. The SPOTFIRE® System represents a pinnacle in molecular infectious disease diagnostics, leveraging FILMARRAY® technology to deliver multiplex PCR solutions. It automates molecular testing processes across one to four modules, ensuring swift and precise results that empower healthcare professionals in making informed decisions at the point of care.
Cepheid, a key player in molecular diagnostics under Danaher Corporation's Diagnostics platform, focuses on enhancing healthcare through innovative, user-friendly molecular systems and tests. By automating intricate manual procedures, Cepheid enables institutions of all sizes to conduct precise genetic testing efficiently. Leveraging robust molecular biology expertise, the company prioritizes applications crucial for rapid and accurate diagnostics, including infectious diseases and cancer management. Cepheid’s GeneXpert® Family of Systems revolutionizes decentralized testing with fast, accurate PCR results. Ideal for hospitals and near-patient settings, these systems offer fully automated sample processing, minimal hands-on time, and rapid results within one hour. Features include LIS/EMR interfaces and closed cartridge technology for contamination prevention. Designed for primary care, urgent care, and pediatric settings, GeneXpert® ensures efficient, reliable diagnosis and treatment in a single visit.
Molbio Diagnostics introduces the "Truelab® Real Time quantitative micro PCR system," featuring "Truenat™ micro PCR Chips" for simplified Real Time PCR testing in all lab settings, including near-patient environments. With a diverse menu of Truenat™ assays for diseases like TB, Covid-19, HCV, HPV, and Influenza, this portable technology enables early, accurate diagnosis and immediate treatment initiation at the point of care. The platform is infrastructure-independent, offering a comprehensive end-to-end solution for disease diagnosis with robust, affordable assays and wireless data transfer capability, transforming global infectious disease management.
QIAGEN, headquartered in the Netherlands, leads globally in Sample to Insight solutions, facilitating molecular insights from various sample types. QIAGEN serves a wide array of customers worldwide in Molecular Diagnostics and Life Sciences, encompassing human healthcare, academia, pharmaceutical R&D, and industrial applications such as forensics. Qiagne provides an efficient syndromic test solution such as QIAstat-Dx. QIAstat-Dx Panels redefine simplicity with less than one minute of hands-on time and a seamless sample-to-result workflow. The QIAstat-Dx Respiratory Panel Plus aids clinical decision-making for upper respiratory infections, detecting 21 viral and bacterial targets. Originally authorised as the QIAstat-Dx Respiratory SARS-CoV-2 Panel, it employs real-time PCR technology to amplify multiple genetic targets simultaneously, yielding results in about one hour with minimal hands-on time.
Roche, the world's largest biotechnology company and a leader in in-vitro diagnostics, is dedicated to scientific excellence in developing medicines and diagnostics that save lives. As a pioneer in personalized healthcare, Roche integrates diagnostics, pharmaceuticals, and clinical data insights to enhance patient care. The cobas liat system exemplifies this commitment with its SARS-CoV-2, Influenza A/B & RSV nucleic acid test. This automated, rapid multiplex real-time RT-PCR test simultaneously detects and differentiates SARS-CoV-2, influenza A, influenza B, and RSV RNA in nasal and nasopharyngeal swabs from symptomatic individuals. Authorized for point-of-care use under CLIA, the cobas liat system automates the entire testing process, delivering reliable results in 20 minutes or less. It simplifies workflows and requires minimal training, making molecular testing accessible in various near-patient settings, thus aiding timely patient care decisions.
